Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCOLR’s sales and earnings

This article was originally published in The Tan Sheet

Executive Summary

SCOLR Pharma's net revenues in its fiscal 2007 declined 13 percent to $2 million, the Bellevue, Wash.-based firm says in a March 11 release. Royalty income related to SCOLR's alliance with Perrigo increased 38 percent to $1.2 million in 2007, however, the gain was offset by a decrease in research and development revenue associated with the termination of an agreement with Wyeth Consumer Healthcare, the firm notes. SCOLR's net loss for the year was $10.6 million compared to $10.7 million in 2006. Achievements in 2007 include the completion of two of three product performance trials to evaluate the safety and efficacy of OTC 12-hour ibuprofen with controlled delivery technology (1"The Tan Sheet" Nov. 5, 2007, In Brief). The third trial is slated for completion by the end of the second quarter this year, and the firm plans to submit its new drug application for the product in the second half of the year...

You may also be interested in...



SCOLR starts studies

SCOLR Pharma announces Nov. 1 the start of the first of three trials to evaluate the safety and efficacy of its OTC 12-hour CDT-based ibuprofen. The Bellevue, Wash.-based firm expects to complete the trials of its controlled delivery technology ibuprofen by the end of the first quarter of 2008, and plans to file a new drug application in the second half of 2008...

Health Sector On High Alert As Wuhan Coronavirus Spreads

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.

Topics

UsernamePublicRestriction

Register

PS101490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel